Fibroblast growth factor binding protein (FGF-BP) is a secreted protein that binds FGF-1 and FGF-2 and is involved in mobilization and activation of FGFs from the extracellular matrix. FGF-BP overexpression as well as ribozyme-mediated reduction of endogenous FGF-BP revealed that FGF-BP can be rate-limiting for tumor growth and angiogenesis. Recent studies showed that FGF-BP expression is up-regulated during early phases of tumorigenesis, indicating that the role of FGF-BP in angiogenesis is a critical early step in the development and progression of tumors. Human papillomavirus type 16 (HPV 16) is highly associated with the development of anogenital cancers. Here we demonstrate that the stable expression of the E6 oncogene of HPV 16 leads to an activation of the FGF-BP promoter in primary human foreskin keratinocytes (one of the natural host cells of these viruses). This is associated with an increase in the steady state levels of FGF-BP mRNA and FGF-BP protein in cells stably expressing E6. Transient E6 expression revealed that the observed activation of the FGF-BP promoter by the viral oncogene is an early process which is independent from immortalization/ transformation events in the cells. Oncogene (2001) 20, 7430 ± 7436.
Keywords: ®broblast growth factor binding protein; HPV16; E6 oncogene; E7 oncogene; promoter Fibroblast growth factors (FGFs) are a family of 21 heparin-binding polypeptide growth factors that play an important role in embryonic development as well as in tumorigenesis. They display neurotrophic activity and stimulate angiogenesis during tumor growth and wound healing (Burgess and Maciag, 1989; Folkman and Klagsbrun, 1987 ; for review see: Powers et al., 2000) . In contrast to most other members of the FGF family, the acidic-(FGF-1) and the basic-(FGF-2) ®broblast growth factors lack a signal peptide for extracellular export; nevertheless, these growth factors are also extracellularly located (Burgess and Maciag, 1989; Mason, 1994) . FGF-1 and 2 bind to heparan sulfate proteoglycans of the extracellular matrix. This binding inactivates the growth factor activities of FGF-1 and 2 (Vlodavsky et al., 1987) . In addition to the heparan sulfate binding, FGF-1 and 2 also bind to the so-called FGF binding protein (FGF-BP). FGF-BP possesses a canonical extracellular signal peptide and is therefore secreted. It binds non-covalently (in a reversible manner) to FGF-1 and 2 in the extracellular matrix, thereby modulating the growth-stimulating activities of FGF-1 or 2 (Wu et al., 1991) . It has been shown that the binding of FGF to FGF-BP mobilizes FGF-2 from the heparan sulfate proteoglycans of the extracellular matrix, leading to the activation of growth factor activities of FGF-2 (Czubayko et al., 1994 (Czubayko et al., , 1997 . Activated FGF-2 can act as an`angiogenic switch' molecule inducing angiogenesis, as has been demonstrated in nontumorigenic adrenal carcinoma cells (SW13) (Czubayko et al., 1994) .
An expression of FGF-BP has been so far described in various human squamous cell carcinomas (SSCs) (for instance SSCs from head and neck region) and in several other cell lines of dierent origin, such as in colorectal adenocarcinoma cell lines, as well as in primary keratinocytes (Czubayko et al., 1994; Wu et al., 1991) . An up-regulation of FGF-BP mRNA was found in the early stages of embryonic mouse development and during carcinogen-induced transformation of adult murine skin, which was associated with histological changes that can be characterized as preneoplastic (Kurtz et al., 1997) .
In accordance with these ®ndings are results that FGF-BP gene transcription is induced by treatment of SCC cell lines with the carcinogen 12-O-tetradecanoylphorbol-13-acetate (TPA) (Harris et al., 1998) or by treatment with epidermal growth factor (EGF) (Harris et al., 2000a) . Analysis of the FGF-BP promoter showed that TPA and EGF induction is mediated within the ®rst 118 base pairs of the proximal promoter and requires several positive regulatory cis-elements in the FGF-BP promoter including Sp1, AP-1, and C/EBP. Additionally, a negative regulatory non-canonical E-box element was found, which represses FGF-BP promoter activity through binding of a protein complex in which USF, c-myc and Max proteins might be involved, as demonstrated by in vivo gel shift analysis (Harris et al., 2000b) . Recently it has been shown that the serum-dependent induction of FGF-BP transcription is mediated through activation of protein kinase C, leading to the activation of ERK and p38 MAP kinase (Harris et al., 2001) . The C/EBP element of the FGF-BP promoter is required for the serum response of this promoter (Harris et al., 2001) .
The described activating functions of FGF-BP in angiogenesis and the observed FGF-BP expression in various tumor tissues suggest that FGF-BP activation is a critical early step in the multistep process of tumorigenesis and tumor progression. We analysed here whether the HPV oncoproteins E6 or E7 of thè high risk' HPV type 16 in¯uence FGF-BP promoter activity in the transition phase between senescent and immortal growth in primary human foreskin keratinocytes, a natural host cell of these viruses.
HPVs are epitheliotropic viruses which induce benign neoplasia during their normal life cycle (de Villiers, 1989) . The subgroup of the so-called`high risk' HPVs (e.g. HPV-16 and HPV-18) not only induce benign neoplasia of the anogenital mucosa, but are also highly associated with cervical cancer (zur Hausen, 1991) . Recent data furthermore suggest that these viruses may be a risk factor for SSC of the head and neck (Mork et al., 2001) . Immortalizing and transforming functions of the HPV oncogenes E6 and E7 have been demonstrated in various tissue culture systems (reviewed in Mansur and Androphy, 1993; StoÈ ppler et al., 1994) . The oncogenic potential of these viral proteins is at least in part due to their ability to interfere with the function of two cellular suppressor proteins, p53 (E6) and the retinoblastoma susceptibility gene product, Rb (E7). The E6 protein binds p53 and induces enhanced ubiquitin-dependent p53 degradation (Huibregtse et al., 1991 (Huibregtse et al., , 1993 Schener et al., 1990 Schener et al., , 1992 thereby also in¯uencing the transcriptional activities of the multifunctional tumor suppressor p53. Additionally, p53-independent transcriptional transactivation and repression have been observed in E6-expressing cells (Crook et al., 1991; Etscheid et al., 1994; Kinoshita et al., 1997; Ronco et al., 1998; Shino et al., 1997) . Recently it has been demonstrated that E6 expression can lead to an inactivation of histone acetyltransferase activity of the p300/CBP family, which results in a repression of p300/CBP protein-binding promoters (Patel et al., 1999; Zimmermann et al., 1999) . Furthermore, it has been shown in primary human keratinocytes that the expression of HPV`high risk' E6 proteins leads to a telomerase activity in these normally telomerase activity-negative cells (Klingelhutz et al., 1996; StoÈ ppler et al., 1997) . A telomerase activity is generally not observed in somatic cells of multicellular eukaryotes, but germ line cells and most tumors and tumor-derived cell lines (more than 90%) possess telomerase activity (Kim et al., 1994) .
The transforming activities of HPV E7 oncoproteins are related to their Rb-binding capabilities (Davies et al., 1993; Dyson et al., 1989 Dyson et al., , 1992 ). An E7/Rb binding leads to the abolishment of the cell cycle control function of the Rb protein, which in its active hypophosphorylated form arrests the cells in the G1 phase of the cell cycle (for a review see Goodrich and Lee, 1993) . The E7/Rb interaction leads to a release of the cellular transcriptional transactivator E2F from Rb, resulting in the transcriptional activation of various cellular E2F protein-binding promoters (Dalton, 1992; Davies et al., 1993; Dyson et al., 1989; Imai et al., 1991; Mudryi et al., 1990) , and inactivating at the same time the transcriptional silencing complex consisting of a histone deacetylase, Rb and E2F (Brehm et al., 1998 (Brehm et al., , 1999 Dahiya et al., 2000; Park et al., 2000) .
Both HPV oncogenes modulate the transcription of cellular genes through dierent mechanisms, thereby in¯uencing the cell cycle control in HPV-infected cells. We investigated separately the eects of HPV`high risk' E6 and E7 oncogene expression on the promoter activity of the`angiogenic switch' protein FGF-BP. The expression of a`high risk' HPV E6 or E7 oncogene leads in primary human foreskin keratinocytes to an increase in the in vivo growth potential of these cells in comparison to non-HPV oncogenetransduced cells (Klingelhutz et al., 1994 (Klingelhutz et al., , 1996 StoÈ ppler et al., 1997) . The HPV oncogene-expressing cells are able to bypass the Hay¯ick or M1-crisis, the normal restriction point of senescent cell growth, and enter the stage of the`extended life span'.`Extended life span' cells are not immortalized; these cells need to pass a second crisis ± the M2 or immortalization crisis ± before the cells have gained immortal growth characteristics. The present analysis was carried out in non-immortalized primary human foreskin keratinocytes during the HPV oncogene-induced`extended life span' of these cells as well as during the`pre-extended life span' phase during the normal senescent growth phase of primary cells. This allowed us to analyse HPV oncogene-dependent eects on FGF-BP promoter activity independently from immortalization and transformation events.
We infected primary human foreskin keratinocytes with recombinant retroviruses expressing the HPV 16 E6 or E7 oncogenes. The transduced cells were selected through a retrovirus-transferred antibiotic resistance (Miller and Rosman, 1989; StoÈ ppler et al., 1997) . Successfully transduced cells were able to bypass the M1-crisis, which occurs in non-HPV oncogene-expressing keratinocytes between passages 12 and 16, and the resulting`extended life span' cells were transiently transfected with a luciferase reporter gene vector, which was driven by the full length FGF-BP promoter as described in the legend to Figure 1 . We observed that transcriptional activity of the transfected FGF-BP promoter was increased in the E6-expressing`extended life span' keratinocytes, in comparison to E7-expressing`extended life span' keratinocytes, E6-plus E7-expressing immortalized human keratinocytes, and non-HPV oncogene-transduced primary human keratinocytes (Figure 1 ). An SV40 promoter-driven reporter gene (renilla luciferase) was co-transfected in all experiments, allowing us to normalize the data for dierences in transfection eciency. The co-transfection was carried out using a 1000-fold molar excess of FGF-BP promoter in comparison to the renilla luciferase-expressing control vector. A second renilla luciferase expression plasmid (CMV renilla luciferase) was used in order to exclude that the measured dierences in the FGF-BP promoter activities were artefacts due to dierences in the promoter activity of the SV40 renilla luciferase control plasmid in the various transduced cells. No dierences after normalization for transfection activities with the FGF-BP promoter or the CMV-driven renilla control vector were observed (data not shown). Still, transcriptional activity for the control plasmids could be higher in one of the cell cultures, due to a higher transfection eciency in comparison to other HPV oncogene-expressing cell cultures. To rule out this possibility, we transfected the dierent cells with a b-galactosidase control plasmid, followed by X-Gal staining. Counting of the blue-stained cells in relation to untransfected cells revealed an identical transfection eciency in all transfected cultures (data not shown).
The observed dierences in FGF-BP promoter construct activity prompted us to measure FGF-BP mRNA levels by Northern blotting, in order to determine if the observed increase in FGF-BP promoter construct activity correlated with increased steady state levels of mRNA of the chromosomal FGF-BP gene. As seen in Figure 2a , the steady state level of cellular FGF-BP mRNA detected by Northern blotting was increased in E6-expressing cells in comparison to E7-expressing cells. The Northern blot results were normalized to steady state levels of GAPDH mRNA as well as to steady state levels of b-actin mRNA. The normalization to both GAPDH mRNA levels ( Figure 2a ) and to b-actin mRNA levels (data not shown) demonstrated that the steady state level of FGF-BP mRNA in E6-expressing cells was about 2.5-fold higher in E6-than E7-expressing cells. This dierence correlated with the approximate fourfold higher activity of the FGF-BP reporter construct in E6-than in the E7-expressing cells (Figure 1) .
We furthermore investigated if the increased steady state FGF-BP mRNA levels of E6-expressing cells in comparison to E7-expressing cells resulted also in increased steady state FGF-BP protein levels in comparison to E7-expressing cells. As demonstrated in Figure 2b , Western blot analysis revealed that E6 cells possessed a twofold higher steady state level of FGF-BP protein than E7-expressing cells.
Next we compared FGF-BP promoter activity during early and late passages in the`extended life span' in order to determine if the eect of E6 expression on FGF-BP promoter activity was dependent upon changes ± for instance increased genomic instability ± occurring during the`extended life span'. Nearly identical FGF-BP promoter activities were observed at early passage numbers (M1 crisis of non-HPV-transduced cells occurred typically between passage numbers 12 and 16, dependent upon the primary keratinocyte isolate used, data not shown) and late passage number E6-expressing`extended life span cells' (Figure 3a ) (M2 crisis of E6-and E7-expressing cells occurred typically between passage numbers 36 and 42, dependent upon the primary keratinocyte isolate used, data not shown). The increased FGF-BP promoter activity was therefore independent of the passage number during thè extended life span' in E6-transduced primary human keratinocytes, suggesting that the observed eect of E6 expression on FGF-BP promoter activity is independent of further cellular changes which might occur during the`extended life span' phase.
We transiently co-transfected an SV40 early promoter-driven E6 expression vector together with the FGF-BP luciferase reporter construct in primary Figure 1 HPV-16 E6 induces transcriptional activity of the FGF-BP promoter. Primary human foreskin keratinocytes (HFK) as well as HPV 16 E6-, HPV16 E7-or E6-plus E7-expressing keratinocytes (E6/7) were cultured in Keratinocyte Serum Free Medium, supplemented with epidermal growth factor (EGF) and bovine pituitary extracts (K-SFM, Life Technologies, Gaithersburg, MD, USA) at 378C, 5% CO 2 . Twenty thousand cells were seeded into each well of a 6-well-plate and were transiently transfected with 1 mg pBP-Luc (full length promoter from 71060 to +62 of FGF-BP, cloned by PCR technology using as template chromosomal DNA from primary human foreskin keratinocytes, inserted into the promoterless pGL3 ®re¯y luciferase reporter vector) or empty pGL3 in cotransfection with 1ng SV40-driven renilla luciferase pRL-SV40 using 3 ml Fugene (Roche Diagnostics GmbH, Mannheim) in 500 ml K-SFM without EGF and bovine pituitary extract supplements. After 6 h 1.5 ml fresh K-SFM with supplements were added. After 54 h cells were lysed, and luciferase activity was measured with the Dual Luciferase Assay (Promega, Madison, WI, USA) as recommended by the vendor. Depicted are representative data (mean+s.e.mean of triplicate samples) after normalization with the transfection eciency control pRL-SV40. Almost identical data were obtained in three independent transfections HPV16 E6 effect on FGF-BP expression H Sto Èppler et al human keratinocytes during their senescent life span in order to further analyse if the observed increased FGF-BP promoter activity of E6-expressing cells is independent of an`extended life span'. A 1.5 ± 2-fold increase in transcriptional activity was observed 72 h after transient transfection of these cells (Figure 3b ). This demonstrates that the expression of E6 alone, without further cellular changes, is sucient to upregulate the FGF-BP promoter in non-transformed primary human keratinocytes during their senescent growth phase. It has already been described that E7-expressing primary keratinocytes possess an increased p53 steady state level in comparison to non-HPV oncogeneexpressing keratinocytes as well as to E6-expressing keratinocytes in which p53 levels are further reduced (Demers et al., 1994; StoÈ ppler et al., 1998) . As previously shown, the up-regulated p53 steady state level in E7-expressing cells led to an increase in the promoter activity of a p53-dependent promoter. By transiently transfecting the p53-dependent reporter plasmid (pp53TA-Luc) into the E7 expressing`extended life span' cells, we demonstrate that p53 was also in the here analysed E7 expressing cells functionally active as a transcriptional transactivator. As demonstrated in Figure 4 , the promoter activity of a reporter gene driven by a p53-dependent promoter in E7-expressing`extended life span' cells was 5 ± 8-fold increased in comparison to E6-or non-HPV oncogeneexpressing primary human keratinocytes. Nevertheless it is unlikely that the elevated promoter activity of the FGF-BP promoter in E6-expressing cells in comparison to E7-expressing cells is due to dierences in the steady state levels of p53 in these cells. HPV 16 E6-plus E7-expressing immortalized keratinocytes also possess a decreased steady state level of p53 (StoÈ ppler et al., 1998) , but these cells do not demonstrate an elevated FGF-BP promoter activity similar to E6-expressing cells (Figure 1) .
In summary, the expression of the`high risk' HPV 16 E6 protein is sucient to induce an increased promoter activity in primary keratinocytes transiently transfected with an FGF-BP reporter plasmid in comparison to non-HPV oncogene-expressing cells or HPV 16 E7 protein-expressing cells. The observed elevated promoter activity of the transiently transfected FGF-BP reporter plasmid in E6-expressing cells correlates with the observed increased steady state Total RNA was isolated from HPV 16 E6-or E7-expressing keratinocytes using Tri reagent (Sigma) according to the manufacturer's instructions. Ten mg of total RNA from each cell line were separated electrophoretically in a formaldehyde agarose gel, blotted onto Hybond-N nylon membrane (Amersham Pharmacia) by capillary action and hybridized with a random-labeled probe from the FGF-BP open reading frame as described previously (Czubayko et al., 1994) . Blots were washed (0.1% SDS, 0.16SSC, 428C) and exposed to X-ray ®lm (Biomax MS, Eastman Kodak, Rochester, NY, USA). After quanti®cation using densitometry scans, blots were stripped (0.016SSC at 958C for 10 min) and reprobed with a probe speci®c for GAPDH or b-actin mRNA. GAPDH-normalized FGF-BP mRNA levels are shown (mean+s.e.mean). (b) Western blot analysis of steady state protein levels of FGF-BP. About 150 000 HPV 16 E6-or E7-expressing keratinocytes were lysed in 1% SDS, and after heat denaturation approximately 9 mg protein extract was analysed by Western blotting as described (Aigner et al., 2001) levels of mRNA of the cellular FGF-BP gene in E6-expressing cells in comparison to E7-expressing cells. Furthermore, Western blot analysis revealed that the elevated FGF-BP mRNA levels in E6-expressing cells were associated with elevated steady state levels of FGF-BP protein in E6-expressing cells in comparison to E7-expressing cells. Even though E7-expressing cells possess elevated steady state levels of p53 in comparison to E6-expressing cells, which is known to transcriptionally modulate the expression of various cellular genes, it is unlikely that the observed dierences in FGF-BP promoter activity are due to dierences in the p53 levels of the cells, because E6-plus E7-expressing cells, which possess p53 levels comparable to E6-expressing cells (StoÈ ppler et al., 1998) , do not demonstrate an elevated FGF-BP promoter activity. The observed elevated FGF-BP promoter activity of E6-expressing cells is independent of immortalization-or transformation-dependent events in the cells. Recently Lopez-Ocejo et al. (2000) demonstrated that the expression of another angiogenesis factor, the vascular endothelial growth factor (VEGF), is upregulated by an HPV 16 E6 oncogene expression in immortalized cells (HaCat, immortalized human keratinocytes; and NIH3T3, mouse ®broblasts). The induction of VEGF promoter activity was p53-independent in these cells.
Our data demonstrate that the HPV 16 E6 oncoprotein up-regulates FGF-BP expression independently of immortalization and transformation events. The role of the HPV 16 E6 oncoprotein in the up-regulation of FGF-BP expression in nonimmortalized cells reported here as well as the recently described role of the E6-dependent upregulation in VEGF in immortalized cells demonstrates that an E6 expression positively in¯uences the angiogenic abilities of cells. Angiogenesis is widely accepted as an important and potentially rate-limiting part of a multistage progression in initial tumor development (for review see Hanahan and Folkman, 1996) . As shown by Arbeit et al. (1996) , in a transgenic multistage model of carcinogenesis, basal keratinocytes were progressively transformed into SCC by HPV16 oncogenes. In this model the angiogenic switch was evident prior to the development of the squamous cancers. Increased angiogenesis could be detected as early as during the progression of the lesions from hyperplastic to dysplastic stages Primary human keratinocytes during their senescent growth phase (HFK) were transiently co-transfected with an FGF-BP promoter-driven luciferase reporter gene plasmid as well as fourfold excess of E6 expression plasmid or empty expression vector as negative control. Brie¯y, 1 mg pSV-E6 or pSV, 0.125 mg pBP-Luc and 2 ng pRL-SV40 were incubated with 3.5 ml Fugene tm 6 and 200 ml K-SFM (lacking the supplements EGF and pituary extract) for 30 min and then added to 25 000 cells, which had been seeded into a well of a 6-well plate the day before. After 72 h cells were lysed, and luciferase activity was measured using the Dual Luciferase Assay (Promega). Depicted are representative data (mean+s.e.mean of triplicate samples) after normalization with transfection eciency control pRL-SV40. Three independent experiments were carried out, with similar results HPV16 E6 effect on FGF-BP expression H Sto Èppler et al Coussens et al., 1996) . Also, in vivo, a correlation between HPV infection and increased angiogenesis in the uterine cervix could be shown. Nair et al. (1999) demonstrated increased CD34 expression associated with the presence of HPV 16 and 18 in uterine cervical lesions and tumors. It is tempting to speculate that the observed E6 expression-dependent up-regulation of the FGF-BP protein levels in the non-immortalized epithelial cells is causally associated with the increased risk of malignent conversion of HPV-induced anogenital lesions. Mutational analysis of the FGF-BP promoter as well as of the HPV 16 E6 gene is currently underway in order to further characterize the upregulation of the FGF-BP promoter through a`high risk' HPV E6 expression.
In conclusion, our results show an intriguing correlation between the expression of the angiogenic switch molecule FGF-BP and the expression of the HPV 16 E6 oncoprotein in human keratinocytes. As demonstrated by transient transfections, up-regulation of FGF-BP promoter activity is an immediate event independent of immortalization events. Figure 4 p53 of HPV16 E7-expressing cells is transcriptionally active. Primary human foreskin keratinocytes (HFK), as well as HPV 16 E6-or E7-expressing, keratinocytes were transiently cotransfected with 1 mg of a luciferase expression vector driven by a p53-dependent promoter (pp53-TA-Luc, Clontech) and 1 ng of the SV40-driven renilla luciferase vector pRL-SV40. Luciferase activity was measured after 54 h. Representative data (mean+ s.e.mean of triplicate samples) after normalization with transfection eciency control pRL-SV40 are shown
